The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-2807
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The Investigation of Lipoxygenases as Therapeutic Targets in Malignant Pleural Mesothelioma ; day:2 ; month:4 ; year:2019 ; pages:1-11
Pathology & oncology research ; (2.4.2019), 1-11
- Creator
-
Oguh-Olayinka, Lily
Agarwal, Vijay
Ranatunge, Dulani
Campbell, Anne
Laufer, Stefan
Cawkwell, Lynn
Lind, Michael J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12253-019-00652-x
- URN
-
urn:nbn:de:101:1-2019042313302416824795
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:56 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Oguh-Olayinka, Lily
- Agarwal, Vijay
- Ranatunge, Dulani
- Campbell, Anne
- Laufer, Stefan
- Cawkwell, Lynn
- Lind, Michael J.
- SpringerLink (Online service)
Other Objects (12)
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma
Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
Management of malignant pleural mesothelioma—part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG)
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
Metabolic rewiring and redox alterations in malignant pleural mesothelioma
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma
Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
Management of malignant pleural mesothelioma—part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG)
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
Metabolic rewiring and redox alterations in malignant pleural mesothelioma
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma
Identification of CD24 as a potential diagnostic and therapeutic target for malignant pleural mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
BCL-XL is an actionable target for treatment of malignant pleural mesothelioma
Management of malignant pleural mesothelioma—part 2: therapeutic approaches : Consensus of the Austrian Mesothelioma Interest Group (AMIG)
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy